REG - ValiRx PLC - Exercise of Warrant

ValiRxAnnouncement

07/09/2020 13:30

RNS Number : 2523Y
  
ValiRx PLC
  
07 September 2020
  
 

VALIRX PLC
("ValiRx", the "Company" or the "Group")
Exercise of Warrant
 
London, UK 7 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces  it has received notification for the exercise of a warrant over 215,384 ordinary shares in the Company at an exercise price of 16.25 pence per share providing the Company with proceeds of £35,000 ("Warrant Exercise").
 
Application will be made to the London Stock Exchange to admit the 215,384 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 11 September 2020.  The new ordinary shares will rank pari passu with the existing ordinary shares.
 
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 57,319,423 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 
 
For further information please contact:








ValiRx plc


Tel: +44 (0) 20 7073 2628
www.valirx.com




Suzanne Dilly


Suzanne.Dilly@valirx.com




 
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti


 
Tel: +44 (0) 20 7213 0880




 
Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker


 
Tel: +44 (0) 20 7469 0930




 


 




 


 




 


 




 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
IOELRMTTMTMMBFM